Semaglutide: the complete weight loss guide.

1. What is semaglutide?

Semaglutide is an injectable medication in the family of GLP-1 receptor agonists (glucagon-like peptide-1). It was originally developed to treat type 2 diabetes and FDA-approved in 2017 under the brand name Ozempic®. In 2021, the FDA approved the same molecule at a higher dose specifically for weight loss, under the brand name Wegovy®. Same active molecule — the difference is dose and product label.

Beyond diabetes, semaglutide has become one of the most-studied medications for obesity, with large clinical trials showing sustained weight loss, blood pressure improvement, reduced cardiovascular risk, and improvements in metabolic markers like hemoglobin A1c and lipids.

2. How it works in the body

Semaglutide mimics a hormone called GLP-1 that your body produces naturally in the gut after eating. Natural GLP-1 only lasts a few minutes in the bloodstream; semaglutide has a half-life of about one week, enabling a once-weekly injection.

It acts on three main systems:

• Brain: binds GLP-1 receptors in the hypothalamus and other appetite-regulating regions. The result is a reduction in physical hunger and — what many patients describe as the most transformative part — a quieting of the constant mental "food chatter".
• Stomach: slows gastric emptying so food stays in the stomach longer. You feel satisfied on less food and that feeling lasts longer.
• Pancreas: stimulates insulin release when glucose levels are elevated and suppresses glucagon (the sugar-raising hormone). This improves blood glucose control.

3. Efficacy: how much weight people lose

The most cited clinical trial is STEP 1, published in the New England Journal of Medicine in 2021. It included 1,961 adults without diabetes with BMI ≥30 (or class 1 obesity with a comorbidity). Participants on 2.4 mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group.

For perspective: for a woman weighing 200 pounds (90 kg), that's an average loss of about 30 pounds (13.5 kg). A third of participants lost more than 20% of body weight.

Individual results vary by: maximum dose reached (many patients don't get to 2.4 mg), adherence to weekly injections, parallel diet and activity changes, and genetic factors. It's not a "magic drug" — it works best combined with lifestyle changes and ongoing medical follow-up.

4. Dosing and titration

Semaglutide for weight loss always starts with a low dose and increases gradually ("titration") every 4 weeks. The standard schedule is:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

The slow titration exists to minimize gastrointestinal side effects. If side effects are intolerable at any dose, a licensed provider can extend the time at that dose or keep you at a lower dose permanently if results are good there.

5. Side effects

The most common side effects, reported in more than 10% of patients in STEP 1, are gastrointestinal:

• Nausea (44%): most common in the first 2–4 weeks after dose increases. Usually mild. Strategies: smaller portions, avoid fatty foods, stay hydrated.
• Diarrhea (30%)
• Constipation (24%): worsens with dehydration. Fiber + water.
• Vomiting (25%)
• Abdominal pain (20%)
• Fatigue (11%)

Rare but serious side effects requiring immediate medical attention:

• Acute pancreatitis: persistent severe abdominal pain radiating to the back, with or without vomiting.
• Gallbladder issues: slightly increased risk of gallstones, especially with rapid weight loss.
• Hypoglycemia: rare without diabetes, but possible if combined with insulin or sulfonylureas.
• Severe allergic reactions: severe rash, face/tongue swelling, difficulty breathing.

Absolute contraindication: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Semaglutide carries an FDA "black box warning" for this reason — although the risk was observed in rats and not humans, the FDA maintains the warning out of caution.

6. Who is a candidate?

The FDA approved semaglutide 2.4 mg (Wegovy®) for weight loss in:

• Adults with BMI ≥30 (obesity), or
• Adults with BMI ≥27 and at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease).

Not a candidate for semaglutide:

• Personal or family history of MTC or MEN2.
• Severe prior pancreatitis.
• Pregnancy or actively trying to conceive (recommended to discontinue at least 2 months before conceiving).
• Breastfeeding (limited evidence on milk transfer).
• Severe gastroparesis or other conditions that significantly delay gastric emptying.

A licensed licensed provider must review your full medical history, current medications, allergies, and goals before prescribing. At REMEVi this review happens within 24 hours of the eligibility quiz.

7. Compounded vs. brand semaglutide

Brand semaglutide (Ozempic® for diabetes, Wegovy® for weight loss) is manufactured by Novo Nordisk and went through the full FDA approval process. It's the gold standard — and the most expensive. Without insurance, list prices run $900–$1,400 per month.

Compounded semaglutide is prepared by FDA-authorized compounding pharmacies under an individual individual prescription. These pharmacies source the active ingredient (semaglutide sodium) from FDA-registered suppliers and prepare patient-specific doses. It's not a generic — generics only exist after a patent expires, and semaglutide's patent has not. Compounding is a parallel legal pathway.

Important considerations:

• The final product isn't identical to brand — concentration, pH, preservatives may differ.
• There are no large-scale clinical trials specifically on compounded versions.
• The FDA has warned against products sold as "semaglutide" that don't contain semaglutide sodium (the approved form) but unapproved salts instead. REMEVi only works with pharmacies that use verified semaglutide sodium.
• The legal availability of compounding depends on FDA shortage status. If compounding is restricted, we transition patients to alternatives.

8. Cost and options

Actual cost depends on factors like manufacturer discounts, insurance coverage (many plans don't cover weight-loss medications), and geography. REMEVi's price is direct-pay — transparent, no insurance, no fine print.